Dronabinol is in clinical development for the treatment of spasticity caused by multiple sclerosis (MS). MS is a long-term condition that affects the brain and spinal cord, causing a range of symptoms including spasticity. Spasticity is when the muscles become stiff and resistant to movement, which can be extremely painful. There are currently limited treatment options for patients with spasticity caused by MS.
Dronabinol, administered orally, is a synthetic (artificial) form of the psychoactive component of cannabis, which means it can cause changes to cognitive/emotional processes and reduces pain. Dronabinol may reduce spasticity although the precise mechanism for this effect has not been elucidated. If licensed, dronbionol will offer an additional treatment option for adults with spasticity caused by MS.
Trofinetide is in clinical development for the treatment of females with Rett syndrome (RTT). RTT is a rare genetic disorder that affects brain development, resulting in severe mental and physical disability. In RTT, a protein called insulin-like growth factor 1 (IGF1) in the brain is lower than normal and it is thought that nerve function …